LOGIN

International Epidemiology Databases to Evaluate AIDS

Home >> Publications >> Tenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies.

Publication

Author(s):

Wandeler G, Keiser O, Mulenga L, Hoffmann CJ, Wood R, Chaweza T, Brennan A, Prozesky H, Garone D, Giddy J, Chimbetete C, Boulle A, Egger M; IeDEA Southern Africa Collaboration.

Pub Title:

Tenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies.

Pub Date:

Sep 1 2012

Pub Region(s):

Southern Africa

Journal Issue:

1

Page Number:
41-8

Journal:

Title: 
JAIDS- Journal of Acquired Immune Deficiency Syndromes
Link: 
http://journals.lww.com/jaids/pages/articleviewer.aspx?year=2012&issue=09010&article=00006&type=abstract

PubMed: 22743595
Pub PDF: PDF icon 22743595.pdf

Abstract
OBJECTIVES
: Tenofovir (TDF) is increasingly used in second-line antiretroviral treatment (ART) in sub-Saharan Africa. We compared outcomes of second-line ART containing and not containing TDF in cohort studies from Zambia and the Republic of South Africa (RSA).

METHODS: Patients aged 16 years and older starting protease-inhibitor-based second-line ART in Zambia (1 cohort) and RSA (5 cohorts) were included. We compared mortality, immunological failure (all cohorts), and virological failure (RSA only) between patients receiving and not receiving TDF. Competing risk models and Cox models adjusted for age, sex, CD4 count, time on first-line ART, and calendar year were used to analyze mortality and treatment failure, respectively. Hazard ratios (HRs) were combined in fixed-effects meta-analysis.

FINDINGS: 1687 patients from Zambia and 1556 patients from RSA, including 1350 (80.0%) and 206 (13.2%) patients starting TDF, were followed over 4471 person-years. Patients on TDF were more likely to have started second-line ART in recent years and had slightly higher baseline CD4 counts than patients not on TDF. Overall, 127 patients died, 532 were lost to follow-up, and 240 patients developed immunological failure. In RSA, 94 patients had virologic failure. Combined HRs comparing TDF with other regimens were 0.60 (95% confidence interval [CI]: 0.41 to 0.87) for immunologic failure and 0.63 (0.38-1.05) for mortality. The HR for virologic failure in RSA was 0.28 (0.09-0.90).

CONCLUSIONS: In this observational study, patients on TDF-containing second-line ART were less likely to develop treatment failure than patients on other regimens. TDF seems to be an effective component of second-line ART in southern Africa.

PMID: 22743595 [PubMed - indexed for MEDLINE]

PMCID: PMC3432418

 

The following websites provide guidelines and policies when citing from PubMed®: http://www.ncbi.nlm.nih.gov/books/NBK7243/
http://www.nlm.nih.gov/bsd/policy/cit_format.html

Citation:

Wandeler G, Keiser O, Mulenga L, Hoffmann CJ, Wood R, Chaweza T, Brennan A, Prozesky H, Garone D, Giddy J, Chimbetete C, Boulle A, Egger M; IeDEA Southern Africa Collaboration. Tenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies. J Acquir Immune Defic Syndr. 2012 Sep 1;61(1):41-8. PubMed PMID: 22743595; PubMed Central PMCID: PMC3432418.